glp 1 gastritis GLP-1 Medications and Gastroparesis: What You Should Know Glucagon-Like Peptide-1 Based Therapies: A

DOI: 10.1111/crj.13372 [Google Scholar] Yu M, Wang R, Pei L, Zhang X, Wei J, Wen Y, et al

The consultation itself is a $30 charge separate from the medication, and the call quality and clinical depth were strong

[18] Anterior pituitary [edit] In the anterior pituitary gland, the effects of somatostatin are: Inhibiting the release of growth hormone (GH) [19] (thus opposing the effects of growth hormonereleasing hormone (GHRH)) Inhibiting the release of thyroid-stimulating hormone (TSH) [20] Inhibiting the release of prolactin (PRL) Gastrointestinal system [edit] Somatostatin is homologous with cortistatin (see somatostatin family) and suppresses the release of gastrointestinal hormones Decreases the rate of gastric emptying, and reduces smooth muscle contractions and blood flow within the intestine [19] Inhibits adenylyl cyclase in parietal cells, thereby suppressing gastric acid secretion Suppresses the release of pancreatic hormones Suppresses the exocrine secretory action of the pancreas Synthetic substitutes [edit] Octreotide (brand name Sandostatin, Novartis Pharmaceuticals) is an octapeptide that mimics natural somatostatin pharmacologically, though is a more potent inhibitor of growth hormone, glucagon, and insulin than the natural hormone, and has a much longer half-life (about 90 minutes, compared to 23 minutes for somatostatin)

doi: 10.14309/ajg.0000000000001306 39 PaineP